Learn more about MiPSET’s purpose, vision and commitment to advancing human-relevant microphysiological system technologies through research, training and collaboration.
Australia’s dedicated national centre for advancing, translating and deploying microphysiological systems.
The ARC Training Centre for Micro-Physiological System Technology — MiPSET — is Australia’s dedicated national centre for the development, translation, and deployment of microphysiological systems (MPS): the next generation of human-based testing platforms that are set to replace animal models in medical product development.
We bring together world-class researchers, industry innovators, and regulatory experts from four leading Australian universities — QUT, University of Melbourne, Monash University, and the University of Western Australia — united by a single, urgent goal: ensuring Australia plays a leading role in the global transformation of how medicines are discovered, tested, and brought to life.
Building Australia’s scientific capability, advancing MPS technologies and connecting researchers, industry, government and regulators.
To build world-class capacity and scientific leadership in Australia by developing and integrating technological innovations across the non-animal model value chain — delivering advanced solutions and impactful outcomes.
We equip researchers, scientists, and industry professionals with the skills to innovate, translate, and deploy MPS technologies through a comprehensive, industry-facing training program spanning biodesign, regulation, and commercialisation.
We drive cutting-edge research to move MPS technologies from proof-of-concept in the lab to deployable products in the real world — developing smarter biological models, scalable manufacturing processes, and intelligent sensing systems.
We actively bridge the gap between academia, industry, government, and regulators, forging a collaborative national community that can tackle the hardest problems in MPS technology together.
The future of medical product development requires faster, more reliable and more human-relevant testing technologies.
The global landscape of medicine is changing. Drug testing on animals is costly, slow, and often fails to predict how humans will respond — with nearly 30% of drugs safe in animals proving toxic to humans, and 60% deemed effective in animals offering no benefit in people. Legislation in the US, EU, and UK is already steering the world away from animal testing, and the clock is ticking.
of drugs considered safe in animals may prove toxic to humans.
of treatments effective in animals may offer no benefit in people.
legislation is accelerating the transition away from animal testing.
Discover the researchers, industry leaders and collaborators driving MiPSET’s vision for the future of human-relevant microphysiological system technologies.
